bio pharma industry statistcs

8/6/2019 bio pharma industry statistcs

1/22

A PRACTICUM REPORT

ON

BIO PHARMACEUTICALS

BY

N NEELIMA SAHITYAMBA IB ROLL NO 19


2/22

OBJECTIVE

To give a overview of the biopharm industry. To provide information regarding leading companies in the

industry.

To focus on supply chain activities of bio pharma industry.

To identify governmental support, initiatives provided to theindustry.

To focus on the activities relevant to the industry. To provide with statistical data relevant to the industry for

the past 5 to 10 years.


3/22

METHODOLOGY ADOPTED

I visited a bio pharma company as a part of my

practicum and collected the information regarding

operations happening there

Recorded information related to their imported andexported products.

Gathered information related to drug developmentprocess, leading countries in importing their products

Analyzed the Supply chain of the industry is identified. Collected information related to overall activities being

happening in that organization.


4/22

INTRODUCTION

Biopharmaceuticals are the drugs produced by making use

of biological sources by applying the bio technological

techniques.

Insulin is the first biopharmaceutical product producedindustrially.

Any biopharmaceutical company for producing the drugneed to apply for manufacturing rights i.e. patents

Patents are granted as per patent laws. The patent laws vary from nation to nation depending on

the requirement.

From 1970s only the biopharm sector started its activitiesglobally. And within near time it became a leading sector in

India.

The drugs are manufactured and designed as perregulations of food and drug administration FDA.

Once the drug is manufactured it is subjected to some trialsto release into the market

Drugs to be released into markets takes many years ofclinical trials.


5/22

CLASSIFICATION

BI

P

P

DUCTS

BL

D

F

CT

S ES

G

WT

F

CT

SV

CCI

ES E ZY ES

DDITI

L

P

DUCTS


6/22

INDIAN BIOPHARMACEUTICALS INDUSTRY REPORT

The Indian biopharm industry is fast growing anddeveloping tremendously.

It is the industry that is dominating other sectors, thus it isa leading sector.

The Indian biopharm companies started operations globallyafter liberalization of foreign trade.

This is the sector contributing the major to the Indianeconomy.

Vaccines are major segment of biopharm industry. The industry has about 120 companies involved In

production of the vaccines, drugs.

Vaccines accounts for most revenue generation. Indian biopharm sector is the mostly the export oriented

sector.


7/22

TOP DOMESTIC BIO PHARMA COMPANIES

S.NOCOMPANY

1 Biocon

2 Aventis pharma

3 Eli lilly

4 Shantha biotech

5 Ranbaxy

6 Dr reddys

7 Biological e

8 Serum Institute ofIndia

9 Panacea Biotech

10 Nicholas Piramal

11 Wockhadrt Limited

12 Indian Immunologicals

13 Zydus Cadila

14 GlaxoSmithKline

15 Bharat Serum

16 Krebs Biochemicals and Industries Limited


8/22

TOP GLOBAL BIOPHARMA COMPANIES

S.NO COMPANY

1 Pfizer

2 Novartis

3 Sanofi-Aventis

4 GlaxoSmithKlin

5 AstraZeneca

6 Roche

7 Johnson & Johnson

8 Merck & Co

9 Eli Lilly

10 Abbott

11 Teva

12 Bayer

13 Wyeth

14 Amgen

15 Boehringer

16 Takeda

17 Daiichi Sankyo

18 Novo Nordisk


9/22

LEADING BIO PHARMA COMPANIES IN INDIA WITH THE

FOCUS AREA

company Focus area

Dr reddys cancer

Ranbaxy Respiratory disorders.

Cadila Biotechnology.

AstraZeneca Tuburculosis

Cipla Autoimmune disorders

Bharat Biotech Vaccines.

Shanta Biotech Insulin, Antibiotics

Wockhardt Anti-invectives.


10/22

SUPPLY OF BIO PHARMA PRODUCTS

suppliersuppliesraw materials

manufacturer manufacturesthe

products

qualitycheckisto bedone

properpackageinpharmaproductsisneedetoensure

safetyofgoods

productsare movedto

distributors,pharmistsanddruggists.

distributordistributestotheretailmadicalstoresandalsotothe

doctorsforproductpromotion.

customergetsthedrugsfromretailstoresorfrom doctors.


11/22

SUPPLY CHAIN

The biopharm products are highly sensitive to the temperature

which requires utmost care in handling them. In case of exports

the drugs are to be properly packed to ensure proper delivery of

goods in the supply chain

Pharmacom any

Distributor/agent

s

edicalstore

Doctors

customer


12/22

RESEARCH A EVE PME

Research and develop en is the key area o the pharmasector.

ecause innovationis the basis o

the industry and

spends maximum investments in the innovation.

Nearly up to 15 percent o the sales in the industry isspent on R& .

l ays investment in pharma is risk and

hi

hly uncertainleadin

tohi

h returns ultimately.

It was observed that the pro! it margins o! drugmanufacturing companies is 4 times the margins of top

fortune 500 companies.

R&"

costs spent in us billiondollars

0

20

40

60

80

100

120

140

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Series 1

# eries 1


13/22

CHALLENGES

The biopharm industry faced many challenges to survive in the

industry. .

The challenges are

1)Lack of infrastructure.2)Lack of skilled manpower .3)Highly expensive equipments.4)Release of a new drug takes several years of trials.5)Lack of warehousing .6)Lack of proper srutiny of products.7)Lack of proper care and precautions.8)High competitions in both domestic as well as global

markets.

B y facing many of these challenges also the industry is now

leading the other industries interms of sales and revenues.


14/22

GOVERNMENTAL SUPPORT

In the initial stages of biopharm industry the government

encouraged the industry by providing certain incentives and

benefits.

Like

1)Reduction in the tax rates2)New schemes were introduced by the government.3)Insurance is provided.4)Encouraged innovations through research and development.5)Certain governmental regulations are made flexible.6)Government encouraged bio pharma exports by lowering

tariffs and customs duties.

7)Government focused on the quality of drugs.8)Proper infrastructural facilities are been provided by the

government.


15/22

INDUSTRIAL PRODUCTION OF BIOPHARMACEUTICALS

Biopharmaceuticals are produced by making use of living cells

from biological sources in the bioreactors.

The major problem in the production is with contamination

caused by living cells which leads to spoilage of drug

prod ctionofbio

pharmace ticals

fermentation

recombinanttechnology

geneticallymodifiedcells


16/22

DRUG DISCOVERY PROCESS

drug disc very

re c inic es ing

dos ge c ec

c ec or e ec ivenessnd side e ec s if ny

c ec for ong er us ge re c ions

fdaa rovalafter

revie

arketing

2 to10


17/22

BIO PHARMA INDUSTRY STATISTICS FOR THE YEARS 2003

TO 2010

YEAR WORLDMARKET

IN USDIN BILLIONS

PERCENTAGE GROWTH

ON PREVIOUS YEAR

2003 500 561 9.1

2004 560 603 7.6

2005 605 647 7.2

2006 651 692 7.0

2007 720 740 6.9

2008 788 785 6.1

2009 819 840 7.1

2010 856 875 4.1


18/22

GROWTH OF I DIA BIO PHARMAI DUSTRY FROM2006

The industry faced many fluctuations in the sales from 2006 to

2011

In the below figure it is shown with the sales fluctuations

graphically

YEARSA $ ONG X AXIS SA $ ESA $ ONG Y AXIS


19/22

FACTORS THAT INFLUENCED THE HIGHER DEMAND FOR

BIOPHARMACEUTICALS

1)Increased health conciousness2)Incresed levels of incomes and standards of living3)Lower side effects of biopharm products attracted customers

globally.

4)It is the technological advancement in the pharma sector.5) The demand in abroad for biopharmapoducts,ayurvedic

medicines,herbal medicines is vey much higher than the

demand in india.


20/22

OVERVIEW OF BIO PHARM INDUSTRY

Industry size Today in India there are more than 350 Biotechnology

companies in India .with an employment for over

20,000 scientists.

Geographical

distribution

Most of the companies are located in the major cities

of Delhi, Mumbai, Pune, Chennai, Bangalore,

Hyderabad and Ahmadabad

Output per

annum

The Indian Biopharm revenue is around Rs. 2960

crore

Percentage in

world market

India in 2003 was ranked 3rd in the Asia-Pacific

region and 11th in the world in the number of

biopharm enterprises.

Market

Capitalization

In the year 2008-09 Indian Biopharm Industrys

overall turnover was Rs 12,137 crore


21/22

CONCLUSION

The practicum report on biopharmaceuticals gives us the

overview of the industry.

The statistical data gives an idea related to sales,growth of

industry.

Mainly the supply chain activities mentioned gives the

framework of distribution

The challenges faced by the industry is been overcomed

with the governmenta support in the form of

incentives,benefits,tax reduction,sanctioning required

infrastructural facilities.

The production of drugs industrially is mentioned in the

report.


22/22

REFERENCES

1)WIKIPEDIA2)CYGNUS INDIA.COM3)INDUSTRY REPORTS4)SRIBD.COM

5)BIOPHARMAREVIEW

bio pharma industry statistcs

Documents

Transcript of bio pharma industry statistcs